Drug-loaded nanocarriers: Passive targeting and crossing of biological barriers

Current Medicinal Chemistry

Volumn 19, Issue 19, 2012, Pages 3070-3102

  Rabanel, J M ^a   Aoun, V ^a   Elkin, I ^a   Mokhtar, M ^a   Hildgen, P ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Biological barriers; Drug delivery; Nanocarrier; Oral administration; Passive targeting; Pulmonary administration; Surface properties; Vascular endothelium

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CYTARABINE; DAUNORUBICIN; DEXTRAN DERIVATIVE; DOXORUBICIN; ENKEPHALIN; EXCITATORY AMINO ACID TRANSPORTER; HEPARAN; IRINOTECAN; LIPOSOME; MACROGOL; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; NANOCARRIER; NANOPARTICLE; PENICILLAMINE; PLASMA PROTEIN; POLY(N ISOPROPYLACRYLAMIDE); POLYESTER; POLYGLACTIN; POLYSTYRENE; POLYVINYL ALCOHOL; POVIDONE; PROTEOGLYCAN; UNINDEXED DRUG; VASOPRESSIN;

ANTINEOPLASTIC ACTIVITY; ATOMIC FORCE MICROSCOPY; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; BLOOD FLOW; BLOOD VESSEL; CAPILLARY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TARGETING; DRUG TRANSPORT; EXTRAVASATION; GENETIC HETEROGENEITY; GLIOBLASTOMA; GLIOMA; HEMODYNAMIC MONITORING; HUMAN; HYDROPHILICITY; IMMUNITY; INTERSTITIUM; INTIMA; INTRAVENOUS DRUG ADMINISTRATION; MENINGITIS; MICELLE; MICROVASCULATURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PINOCYTOSIS; REVIEW; RHABDOID TUMOR; SURFACE PROPERTY; VASCULAR ENDOTHELIUM;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84863672079     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800784702     Document Type: Review

References (356)

1. Nel, A.E.; Madler, L.; Velegol, D.; Xia, T.; Hoek, E.M.; Somasundaran, P.; Klaessig, F.; Castranova, V.; Thompson, M. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater., 2009, 8(7), 543-557.
2. Wang, J.; Lu, Z.; Wientjes, M.G.; Au, J.L.S. Delivery of siRNA therapeutics: barriers and carriers. AAPS J., 2010, 12(4), 492-503.
3. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov., 2005, 4(2), 145-160.
4. Jones, M.C.; Leroux, J.C. Polymeric micelles-a new generation of colloidal drug carriers. Eur. J. Pharm. Biopharm., 1999, 48(2), 101-111.
5. Kojima, C. Design of stimuli-responsive dendrimers. Expert Opin. Drug Deliv., 2010, 7(3), 307-319.
6. Bala, I.; Hariharan, S.; Kumar, M.N. PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst., 2004, 21(5), 387-422.
7. Ratzinger, G.; Fillafer, C.; Kerleta, V.; Wirth, M.; Gabor, F. The Role of Surface Functionalization in the Design of PLGA Micro-and Nanoparticles. Crit. Rev. Ther. Drug Carrier Syst., 2010, 27(1), 1-83.
8. Bertrand, N.; Leroux, J.C. The journey of a drug carrier in the body: an anatomo-physiological perspective. J. Control. Release, 2011, doi: 10.1016/j.jconrel.2011.09.098.
9. Hillaireau, H.; Couvreur, P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci., 2009, 66(17), 2873-2896.
10. Grdisa, M. The delivery of biologically active (therapeutic) peptides and proteins into cells. Curr. Med. Chem., 2011, 18(9), 1373-1379.
11. Simone, E.; Ding, B.S.; Muzykantov, V. Targeted delivery of therapeutics to endothelium. Cell Tissue Res., 2009, 335(1), 283-300.
12. Vonarbourg, A.; Passirani, C.; Saulnier, P.; Benoit, J.P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials, 2006, 27(24), 4356-4373.
13. Owens, D.E., 3rd; Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm., 2006, 307(1), 93-102.
14. Lynch, I.; Dawson, K.A. Protein-nanoparticle interactions. Nano Today, 2008, 3(1-2), 40-47.
15. Cedervall, T.; Lynch, I.; Lindman, S.; Berggard, T.; Thulin, E.; Nilsson, H.; Dawson, K.A.; Linse, S. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl. Acad. Sci. U.S.A., 2007, 104(7), 2050-2055.
16. Tabata, Y.; Ikada, Y. Phagocytosis of polymer microspheres by macrophages. Adv. Polym. Sci., 1990, 94, 107-141.
17. Ogawara, K.; Furumoto, K.; Nagayama, S.; Minato, K.; Higaki, K.; Kai, T.; Kimura, T. Pre-coating with serum albumin reduces receptor-mediated hepatic disposition of polystyrene nanosphere: implications for rational design of nanoparticles. J. Control. Release, 2004, 100(3), 451-455.
18. Aderem, A.; Underhill, D.M. Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol., 1999, 17, 593-623.
19. Kanno, S.; Furuyama, A.; Hirano, S. A murine scavenger receptor MARCO recognizes polystyrene nanoparticles. Toxicol. Sci., 2007, 97(2), 398-406.
20. Lundqvist, M.; Stigler, J.; Elia, G.; Lynch, I.; Cedervall, T.; Dawson, K.A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. U.S.A., 2008, 105(38), 14265-14270.
21. Hellstrand, E.; Lynch, I.; Andersson, A.; Drakenberg, T.; Dahlback, B.; Dawson, K. A.; Linse, S.; Cedervall, T., Complete high-density lipoproteins in nanoparticle corona. FEBS J., 2009, 276(12), 3372-3381.
22. Papahadjopoulos, D.; Allen, T.M.; Gabizon, A.; Mayhew, E.; Matthay, K.; Huang, S.K.; Lee, K.D.; Woodle, M.C.; Lasic, D.D.; Redemann, C.; Martin, F.J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U.S.A., 1991, 88(24), 11460-11464.
23. Gref, R.; Minamitake, Y.; Peracchia, M.T.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating polymeric nanospheres. Science, 1994, 263(5153), 1600-1603.
24. Bazile, D.; Prud'homme, C.; Bassoullet, M.T.; Marlard, M.; Spenlehauer, G.; Veillard, M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci., 1995, 84(4), 493-498.
25. Torchilin, V.P.; Omelyanenko, V.G.; Papisov, M.I.; Bogdanov, A.A.Jr.; Trubetskoy, V.S.; Herron, J.N.; Gentry, C.A. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta, 1994, 1195(1), 11-20.
26. Sant, S.; Poulin, S.; Hildgen, P. Effect of polymer architecture on surface properties, plasma protein adsorption, and cellular interactions of pegylated nanoparticles. J. Biomed. Mater. Res. Part A, 2008, 87A(4), 885-895.
27. Gref, R.; Luck, M.; Quellec, P.; Marchand, M.; Dellacherie, E.; Harnisch, S.; Blunk, T.; Muller, R. H. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B Biointerfaces, 2000, 18(3-4), 301-313.
28. Aggarwal, P.; Hall, J.B.; McLeland, C.B.; Dobrovolskaia, M.A.; McNeil, S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev., 2009, 61(6), 428-437.
29. Perrault, S.D.; Walkey, C.; Jennings, T.; Fischer, H.C.; Chan, W.C. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett., 2009, (5), 1909-1915.
30. Mosqueira, V.C.F.; Legrand, P.; Morgat, J.L.; Vert, M.; Mysiakine, E.; Gref, R.; Devissaguet, J.P.; Barratt, G. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm. Res., 2001, 18(10), 1411-1419.
31. Choi, H.S.; Ipe, B.I.; Misra, P.; Lee, J.H.; Bawendi, M.G.; Frangioni, J.V. Tissue-and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett., 2009, 9(6), 2354-2359.
32. Neal, J.C.; Stolnik, S.; Schacht, E.; Kenawy, E.R.; Garnett, M.C.; Davis, S.S.; Illum, L. In vitro displacement by rat serum of adsorbed radiolabeled poloxamer and poloxamine copolymers from model and biodegradable nanospheres. J. Pharm. Sci., 1998, 87(10), 1242-1248.
33. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev., 2001, 53(2), 283-318.
34. Allen, T.M.; Chonn, A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett., 1987, 223(1), 42-46.
35. Dos Santos, N.; Allen, C.; Doppen, A.M.; Anantha, M.; Cox, K.A.K.; Gallagher, R.C.; Karlsson, G.; Edwards, K.; Kenner, G.; Samuels, L.; Webb, M.S.; Bally, M.B. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim. Biophys. Acta, 2007, 1768(6), 1367-1377.
36. Bergstrom, K.; Osterberg, E.; Holmberg, K.; Hoffman, A.S.; Schuman, T.P.; Kozlowski, A.; Harris, J.M. Effects of branching and molecular-weight of surface bound poly(ethylene oxide) on protein rejection. J. Biomater. Sci. Polym. Ed., 1994, 6(2), 123-132.
37. Lacasse, F.X.; Filion, M.C.; Phillips, N.C.; Escher, E.; McMullen, J.N.; Hildgen, P. Influence of surface properties at biodegradable microsphere surfaces: effects on plasma protein adsorption and phagocytosis. Pharm. Res., 1998, 15(2), 312-317.
38. De Jaeghere, F.; Allemann, E.; Feijen, J.; Kissel, T.; Doelker, E.; Gurny, R. Cellular uptake of PEO surface-modified nanoparticles: evaluation of nanoparticles made of PLA: PEO diblock and triblock copolymers. J. Drug Target., 2000, 8(3), 143-153.
39. Moghimi, S.M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res., 2003, 42(6), 463-478.
40. Ishida, T.; Kiwada, H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm., 2008, 354(1-2), 56-62.
41. Li, S.D.; Huang, L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J. Control. Release, 2010, 145(3), 178-181.
42. Moghimi, S.M.; Andersen, A.J.; Hashemi, S.H.; Lettiero, B.; Ahmadvand, D.; Hunter, A.C.; Andresen, T.L.; Hamad, I.; Szebeni, J. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J. Control. Release, 2010, 146(2), 175-181.
43. Moghimi, S.M.; Hamad, I.; Andresen, T.L.; Jorgensen, K.; Szebeni, J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J., 2006, 20(14), 2591-2593.
44. Mosqueira, V.C.F.; Legrand, P.; Gulik, A.; Bourdon, O.; Gref, R.; Labarre, D.; Barratt, G. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials, 2001, 22(22), 2967-2979.
45. Gbadamosi, J.K.; Hunter, A.C.; Moghimi, S.M. PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Lett., 2002, 532(3), 338-344.
46. Essa, S.; Rabanel, J.M.; Hildgen, P. Effect of polyethylene glycol (PEG) chain organization on the physicochemical properties of poly(D, L-lactide) (PLA) based nanoparticles. Eur. J. Pharm. Biopharm., 2010, 75(2), 96-106.
47. Passirani, C.; Barratt, G.; Devissaguet, J.P.; Labarre, D. Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). Pharm. Res., 1998, 15(7), 1046-1050.
48. De Sousa Delgado, A.; Léonard, M.; Dellacherie, E. Surface properties of polystyrene nanoparticles coated with dextrans and dextran-PEO copolymers. Effect of polymer architecture on protein adsorption. Langmuir, 2001, 17(14), 4386-4391.
49. Shehata, T.; Ogawara, K.; Higaki, K.; Kimura, T. Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers. Int. J. Pharm., 2008, 359(1-2), 272-279.
50. Gaucher, G.; Asahina, K.; Wang, J.H.; Leroux, J.C., Effect of poly(N-vinyl-pyrrolidone)-block-poly(D, L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles. Biomacromolecules, 2009, 10(2), 408-416.
51. Sahoo, S.K.; Panyam, J.; Prabha, S.; Labhasetwar, V. Residual polyvinyl alcohol associated with poly (d, l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Release, 2002, 82(1), 105-114.
52. Roser, M.; Fischer, D.; Kissel, T. Surface-modified biodegradable albumin nano-and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur. J. Pharm. Biopharm., 1998, 46(3), 255-263.
53. Gessner, A.; Lieske, A.; Paulke, B.R.; Muller, R.H. Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur. J. Pharm. Biopharm., 2002, 54(2), 165-170.
54. Choi, H.S.; Liu, W.; Misra, P.; Tanaka, E.; Zimmer, J.P.; Itty Ipe, B.; Bawendi, M.G.; Frangioni, J.V. Renal clearance of quantum dots. Nat. Biotechnol., 2007, 25(10), 1165-1170.
55. Estephan, Z.G.; Schlenoff, P.S.; Schlenoff, J.B. Zwitteration as an alternative to PEGylation. Langmuir, 2011, 27(11), 6794-6800.
56. Ehrenberg, M.S.; Friedman, A.E.; Finkelstein, J.N.; Oberdorster, G.; McGrath, J.L. The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomaterials, 2009, 30(4), 603-610.
57. Gabizon, A.; Papahadjopoulos, D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta, 1992, 1103(1), 94-100.
58. Yamamoto, Y.; Nagasaki, Y.; Kato, Y.; Sugiyama, Y.; Kataoka, K. Long-circulating poly(ethylene glycol)-poly(D, L-lactide) block copolymer micelles with modulated surface charge. J. Control. Release, 2001, 77(1-2), 27-38.
59. Domanski, D.M.; Klajnert, B.; Bryszewska, M. Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry, 2004, 63(1-2), 189-191.
60. Mayer, A.; Vadon, M.; Rinner, B.; Novak, A.; Wintersteiger, R.; Frohlich, E. The role of nanoparticle size in hemocompatibility. Toxicology, 2009, 258(2-3), 139-147.
61. Huang, R.B.; Mocherla, S.; Heslinga, M.J.; Charoenphol, P.; Eniola-Adefeso, O. Dynamic and cellular interactions of nanoparticles in vascular-targeted drug delivery. Mol. Membr. Biol., 2010, 27(7), 312-327.
62. Fang, C.; Shi, B.; Pei, Y.Y.; Hong, M.H.; Wu, J.; Chen, H.Z. In vivo tumor targeting of tumor necrosis factor-[alpha]-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur. J. Pharm. Sci., 2006, 27(1), 27-36.
63. Allen, L.A.; Aderem, A. Mechanisms of phagocytosis. Curr. Opin. Immunol., 1996, 8(1), 36-40.
64. Koval, M.; Preiter, K.; Adles, C.; Stahl, P.D.; Steinberg, T.H. Size of IgG-opsonized particles determines macrophage response during internalization. Exp. Cell Res., 1998, 242(1), 265-273.
65. Liu, D.; Mori, A.; Huang, L. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim. Biophys. Acta, 1992, 1104(1), 95-101.
66. Champion, J.A.; Katare, Y.K.; Mitragotri, S. Particle shape: a new design parameter for micro-and nanoscale drug delivery carriers. J. Control. Release, 2007, 121(1-2), 3-9.
67. Tao, L.; Hu, W.; Liu, Y.; Huang, G.; Sumer, B.D.; Gao, J. Shape-specific polymeric nanomedicine: emerging opportunities and challenges. Exp. Biol. Med., 2011, 236(1), 20-29.
68. Decuzzi, P.; Pasqualini, R.; Arap, W.; Ferrari, M. Intravascular delivery of particulate systems: does geometry really matter? Pharm. Res., 2009, 26(1), 235-243.
69. Devarajan, P.V.; Jindal, A.B.; Patil, R.R.; Mulla, F.; Gaikwad, R.V.; Samad, A. Particle shape: a new design parameter for passive targeting in splenotropic drug delivery. J. Pharm. Sci., 2010, 99(6), 2576-2581.
70. Sharma, G.; Valenta, D.T.; Altman, Y.; Harvey, S.; Xie, H.; Mitragotri, S.; Smith, J.W. Polymer particle shape independently influences binding and internalization by macrophages. J. Control. Release, 2010, 147(3), 408-412.
71. Geng, Y.; Dalhaimer, P.; Cai, S.S.; Tsai, R.; Tewari, M.; Minko, T.; Discher, D.E. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol., 2007, 2(4), 249-255.
72. Simionescu, M.; Popov, D.; Sima, A. Endothelial transcytosis in health and disease. Cell Tissue Res., 2009, 335(1), 27-40.
73. Stan, R. V. In: Cell-Cell Channels, Baluška, F.; Volkmann, D.; Barlow, P.W., Eds. Landes Biosciences and Springer Science: Georgetown, 2006; pp. 251-266.
74. Tse, D.; Stan, R.V. Morphological heterogeneity of endothelium. Semin. Thromb. Hemost., 2010, 36(3), 236-245.
75. Sarin, H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J. Angiogenes. Res., 2010, 2(1), 14.
76. Singh, A.; Satchell, S.C.; Neal, C.R.; McKenzie, E.A.; Tooke, J.E.; Mathieson, P. W. Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. J. Am. Soc. Nephrol., 2007, 18(11), 2885-2893.
77. Pries, A.R.; Secomb, T.W.; Gaehtgens, P. The endothelial surface layer. Pflugers Arch., 2000, 440(5), 653-666.
78. Rehm, M.; Zahler, S.; Lotsch, M.; Welsch, U.; Conzen, P.; Jacob, M.; Becker, B.F. Endothelial glycocalyx as an additional barrier determining extravasation of 6% hydroxyethyl starch or 5% albumin solutions in the coronary vascular bed. Anesthesiology, 2004, 100(5), 1211-1223.
79. Reitsma, S.; Slaaf, D.W.; Vink, H.; van Zandvoort, M.A.; oude Egbrink, M.G. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch., 2007, 454(3), 345-359.
80. Curry, F.R.; Adamson, R.H. Vascular permeability modulation at the cell, microvessel, or whole organ level: towards closing gaps in our knowledge. Cardiovasc. Res., 2010, 87(2), 218-229.
81. Weinbaum, S.; Tarbell, J.M.; Damiano, E.R. The structure and function of the endothelial glycocalyx layer. Annu. Rev. Biomed. Eng., 2007, 9, 121-167.
82. Raviv, U.; Giasson, S.; Kampf, N.; Gohy, J.F.; Jerome, R.; Klein, J. Lubrication by charged polymers. Nature, 2003, 425(6954), 163-165.
83. Mulivor, A.W.; Lipowsky, H.H. Role of glycocalyx in leukocyte-endothelial cell adhesion. Am. J. Physiol. Heart Circ. Physiol., 2002, 283(4), H1282-H1291.
84. Mounkes, L.C.; Zhong, W.; Cipres-Palacin, G.; Heath, T.D.; Debs, R.J. Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J. Biol. Chem., 1998, 273(40), 26164-26170.
85. Wu, N.Z.; Da, D.; Rudoll, T.L.; Needham, D.; Whorton, A.R.; Dewhirst, M.W. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res., 1993, 53(16), 3765-3770.
86. Toy, R.; Hayden, E.; Shoup, C.; Baskaran, H.; Karathanasis, E. The effects of particle size, density and shape on margination of nanoparticles in microcirculation. Nanotechnology, 2011, 22(11), 115101.
87. McIntosh, D.P.; Tan, X.Y.; Oh, P.; Schnitzer, J.E. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc. Natl. Acad. Sci. U.S.A., 2002, 99(4), 1996-2001.
88. Wang, Z.J.; Tiruppathi, C.; Minshall, R.D.; Malik, A.B. Size and dynamics of caveolae studied using nanoparticles in living endothelial cells. ACS Nano, 2009, 3(12), 4110-4116.
89. Wang, Z.; Tiruppathi, C.; Cho, J.; Minshall, R.D.; Malik, A.B. Delivery of nanoparticle: complexed drugs across the vascular endothelial barrier via caveolae. IUBMB Life, 2011, 63(8), 659-667.
90. Dvorak, A.M.; Feng, D. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J. Histochem. Cytochem., 2001, 49(4), 419-432.
91. Tuma, P.L.; Hubbard, A.L. Transcytosis: crossing cellular barriers. Physiol. Rev., 2003, 83(3), 871-932.
92. Desai, N.P.; Trieu, V.; Hwang, L.Y.; Wu, R.J.; Soon-Shiong, P.; Gradishar, W.J. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer. Drugs, 2008, 19(9), 899-909.
93. Jain, R.K.; Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol., 2010, 7(11), 653-664.
94. Narang, A.S.; Varia, S. Role of tumor vascular architecture in drug delivery. Adv. Drug Deliv. Rev., 2011, 63(8), 640-658.
95. Roberts, W.G.; Palade, G.E. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci., 1995, 108(Pt 6), 2369-2379.
96. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev., 2011, 63(3), 136-151.
97. Hashizume, H.; Baluk, P.; Morikawa, S.; McLean, J.W.; Thurston, G.; Roberge, S.; Jain, R.K.; McDonald, D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol., 2000, 156(4), 1363-1380.
98. Roberts, W.G.; Palade, G.E. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res., 1997, 57(4), 765-72.
99. Hobbs, S.K.; Monsky, W.L.; Yuan, F.; Roberts, W.G.; Griffith, L.; Torchilin, V.P.; Jain, R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U.S.A., 1998, 95(8), 4607-4612.
100. Yuan, F.; Dellian, M.; Fukumura, D.; Leunig, M.; Berk, D.A.; Torchilin, V.P.; Jain, R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res., 1995, 55(17), 3752-3756.
101. Bouzin, C.; Feron, O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist. Updat., 2007, 10(3), 109-120.
102. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 1986, 46(12 Pt 1), 6387-6392.
103. Maeda, H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem., 2010, 21(5), 797-802.
104. Acharya, S.; Sahoo, S.K. PLGA nanoparticles containing various anticancer agents and tumor delivery by EPR effect. Adv. Drug Deliv. Rev., 2011, 63(3), 170-183.
105. Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; Huang, A.; Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res., 1994, 54(4), 987-992.
106. Gabizon, A.; Goren, D.; Horowitz, A.T.; Tzemach, D.; Lossos, A.; Siegal, T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv. Drug Deliv. Rev., 1997, 24(2-3), 337-344.
107. Bae, Y.H.; Park, K. Targeted drug delivery to tumors: myths, reality and possibility. J. Control. Release, 2011, 153(3), 198-205.
108. Maeda, H. Nitroglycerin enhances vascular blood flow and drug delivery in hypoxic tumor tissues: analogy between angina pectoris and solid tumors and enhancement of the EPR effect. J. Control. Release, 2010, 142(3), 296-298.
109. Metselaar, J.M.; Wauben, M.H.M.; Wagenaar-Hilbers, J.P.A.; Boerman, O.C.; Storm, G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum., 2003, 48(7), 2059-2066.
110. Higaki, M.; Ishihara, T.; Kubota, T.; Choi, T. Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J. Pharmacol. Exp. Ther., 2009, 329(2), 412-417.
111. Palmer, T.N.; Caride, V.J.; Caldecourt, M.A.; Twickler, J.; Abdullah, V. The mechanism of liposome accumulation in infarction. Biochim. Biophys. Acta, 1984, 797(3), 363-368.
112. Yuan, F.; Leunig, M.; Huang, S.K.; Berk, D.A.; Papahadjopoulos, D.; Jain, R.K. Mirovascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res., 1994, 54(13), 3352-3356.
113. Holback, H.; Yeo, Y. Intratumoral drug delivery with nanoparticulate carriers. Pharm. Res., 2011, 28(8), 1819-1830.
114. Boucher, Y.; Jain, R.K. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res., 1992, 52(18), 5110-5114.
115. Danhier, F.; Feron, O.; Preat, V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release, 2010, 148(2), 135-146.
116. Netti, P.A.; Berk, D.A.; Swartz, M.A.; Grodzinsky, A.J.; Jain, R.K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res., 2000, 60(9), 2497-2503.
117. Stylianopoulos, T.; Diop-Frimpong, B.; Munn, L.L.; Jain, R.K. Diffusion anisotropy in collagen gels and tumors: the effect of fiber network orientation. Biophys. J., 2010, 99(10), 3119-3128.
118. Stylianopoulos, T.; Poh, M.Z.; Insin, N.; Bawendi, M.G.; Fukumura, D.; Munn, L.L.; Jain, R.K. Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophys. J., 2010, 99(5), 1342-1349.
119. Dreher, M.R.; Liu, W.; Michelich, C.R.; Dewhirst, M.W.; Yuan, F.; Chilkoti, A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst., 2006, 98(5), 335-344.
120. Lee, H.; Hoang, B.; Fonge, H.; Reilly, R.M.; Allen, C. In vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels. Pharm. Res., 2010, 27(11), 2343-2355.
121. Meng, H.; Xue, M.; Xia, T.; Ji, Z.; Tarn, D.Y.; Zink, J.I.; Nel, A.E. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano, 2011, 5(5), 4131-4144.
122. Gaumet, M.; Vargas, A.; Gurny, R.; Delie, F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur. J. Pharm. Biopharm., 2008, 69(1), 1-9.
123. Campbell, R.B.; Fukumura, D.; Brown, E.B.; Mazzola, L.M.; Izumi, Y.; Jain, R.K.; Torchilin, V.P.; Munn, L.L. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res., 2002, 62(23), 6831-6836.
124. Ran, S.; Downes, A.; Thorpe, P.E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res., 2002, 62(21), 6132-6140.
125. Li, Y.; Wang, J.; Wientjes, M.G.; Au, J.L.S. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv. Drug Deliv. Rev., 2011, doi: 10.1016/j.addr.2011.04.006.
126. Thurston, G.; McLean, J.W.; Rizen, M.; Baluk, P.; Haskell, A.; Murphy, T.J.; Hanahan, D.; McDonald, D.M. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest., 1998, 101(7), 1401-1413.
127. Levchenko, T.S.; Rammohan, R.; Lukyanov, A.N.; Whiteman, K.R.; Torchilin, V. P. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int. J. Pharm., 2002, 240(1-2), 95-102.
128. Ho, E.A.; Ramsay, E.; Ginj, M.; Anantha, M.; Bregman, I.; Sy, J.; Woo, J.; Osooly-Talesh, M.; Yapp, D.T.; Bally, M.B. Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties. J. Pharm. Sci., 2010, 99(6), 2839-2853.
129. He, C.; Hu, Y.; Yin, L.; Tang, C.; Yin, C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials, 2010, 31(13), 3657-3666.
130. Labhasetwar, V.; Song, C.; Humphrey, W.; Shebuski, R.; Levy, R.J. Arterial uptake of biodegradable nanoparticles: effect of surface modifications. J. Pharm. Sci., 1998, 87(10), 1229-1234.
131. Akinc, A.; Querbes, W.; De, S.M.; Qin, J.; Frank-Kamenetsky, M.; Jayaprakash, K.N.; Jayaraman, M.; Rajeev, K.G.; Cantley, W.L.; Dorkin, J.R.; Butler, J.S.; Qin, L.L.; Racie, T.; Sprague, A.; Fava, E.; Zeigerer, A.; Hope, M.J.; Zerial, M.; Sah, D.W.Y.; Fitzgerald, K.; Tracy, M.A.; Manoharan, M.; Koteliansky, V.; de Fougerolles, A.; Maier, M.A. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther., 2010, 18(7), 1357-1364.
132. Serda, R.E.; Gu, J.; Bhavane, R.C.; Liu, X.; Chiappini, C.; Decuzzi, P.; Ferrari, M. The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials, 2009, 30(13), 2440-2448.
133. Kommareddy, S.; Amiji, M. Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. J. Pharm. Sci., 2007, 96(2), 397-407.
134. Ganta, S.; Devalapally, H.; Shahiwala, A.; Amiji, M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control. Release, 2008, 126(3), 187-204.
135. Schmaljohann, D. Thermo-and pH-responsive polymers in drug delivery. Adv. Drug Deliv. Rev., 2006, 58(15), 1655-1670.
136. Hak, S.; Reitan, N.K.; Haraldseth, O.; de Lange Davies, C. Intravital microscopy in window chambers: a unique tool to study tumor angiogenesis and delivery of nanoparticles. Angiogenesis, 2010, 13(2), 113-130.
137. Needham, D.; Dewhirst, M.W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv. Drug Deliv. Rev., 2001, 53(3), 285-305.
138. Dreher, M.R.; Liu, W.; Michelich, C.R.; Dewhirst, M.W.; Chilkoti, A. Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. Cancer Res., 2007, 67(9), 4418-4424.
139. Chilkoti, A.; Dreher, M.R.; Meyer, D.E.; Raucher, D. Targeted drug delivery by thermally responsive polymers. Adv. Drug Deliv. Rev., 2002, 54(5), 613-630.
140. Gao, W.; Chan, J.M.; Farokhzad, O.C. pH-responsive nanoparticles for drug delivery. Mol. Pharm., 2010, 7(6), 1913-1920.
141. Sawant, R.R.; Torchilin, V.P. Liposomes as 'smart' pharmaceutical nanocarriers. Soft Matter, 2010, 6(17), 4026-4044.
142. Leroux, J.C.; Roux, E.; Le Garrec, D.; Hong, K.L.; Drummond, D.C. N-isopropylacrylamide copolymers for the preparation of pH-sensitive liposomes and polymeric micelles. J. Control. Release, 2001, 72(1-3), 71-84.
143. Roux, E.; Lafleur, M.; Lataste, E.; Moreau, P.; Leroux, J.C. On the characterization of pH-sensitive liposome/polymer complexes. Biomacromolecules, 2003, 4(2), 240-248.
144. Shin, J.; Shum, P.; Thompson, D.H. Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. J. Control. Release, 2003, 91(1-2), 187-200.
145. Griset, A.P.; Walpole, J.; Liu, R.; Gaffey, A.; Colson, Y.L.; Grinstaff, M.W. Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system. J. Am. Chem. Soc., 2009, 131(7), 2469-2471.
146. Criscione, J.M.; Le, B.L.; Stern, E.; Brennan, M.; Rahner, C.; Papademetris, X.; Fahmy, T.M. Self-assembly of pH-responsive fluorinated dendrimer-based particulates for drug delivery and noninvasive imaging. Biomaterials, 2009, 30(23-24), 3946-3955.
147. Bertrand, N.; Simard, P.; Leroux, J.C. Serum-stable, long-circulating, pH-sensitive PEGylated liposomes. Methods Mol. Biol., 2010, 605, 545-558.
148. Mok, H.; Park, J.W.; Park, T.G. Enhanced intracellular delivery of quantum dot and adenovirus nanoparticles triggered by acidic pH via surface charge reversal. Bioconjug. Chem., 2008, 19(4), 797-801.
149. Poon, Z.; Chang, D.; Zhao, X.; Hammond, P.T. Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia. ACS Nano, 2011, 5(6), 4284-4292.
150. Hatakeyama, H.; Akita, H.; Kogure, K.; Oishi, M.; Nagasaki, Y.; Kihira, Y.; Ueno, M.; Kobayashi, H.; Kikuchi, H.; Harashima, H. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther., 2007, 14(1), 68-77.
151. Danquah, M.K.; Zhang, X.A.; Mahato, R.I. Extravasation of polymeric nanomedicines across tumor vasculature. Adv. Drug Deliv. Rev., 2011, 63(8), 623-639.
152. Helmlinger, G.; Yuan, F.; Dellian, M.; Jain, R.K. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med., 1997, 3(2), 177-182.
153. Kuai, R.; Yuan, W.; Qin, Y.; Chen, H.; Tang, J.; Yuan, M.; Zhang, Z.; He, Q. Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes. Mol. Pharm., 2010, 7(5), 1816-1826.
154. Zhang, J.X.; Zalipsky, S.; Mullah, N.; Pechar, M.; Allen, T.M. Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers. Pharmacol. Res., 2004, 49(2), 185-198.
155. Zhang, Y.; So, M.K.; Rao, J. Protease-modulated cellular uptake of quantum dots. Nano Lett., 2006, 6(9), 1988-1992.
156. Harris, T.J.; von Maltzahn, G.; Lord, M.E.; Park, J.H.; Agrawal, A.; Min, D.H.; Sailor, M.J.; Bhatia, S.N. Protease-triggered unveiling of bioactive nanoparticles. Small, 2008, 4(9), 1307-1312.
157. Mok, H.; Bae, K.H.; Ahn, C.H.; Park, T.G. PEGylated and MMP-2 specifically dePEGylated quantum dots: comparative evaluation of cellular uptake. Langmuir, 2008, 25(3), 1645-1650.
158. Wong, C.; Stylianopoulos, T.; Cui, J.; Martin, J.; Chauhan, V.P.; Jiang, W.; Popovic, Z.; Jain, R.K.; Bawendi, M.G.; Fukumura, D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl. Acad. Sci. U.S.A., 2011, 108(6), 2426-2431.
159. Wolf, S.; Seehaus, B.; Minol, K.; Günter Gassen, H. Die blut-hirn-schranke: eine besonderheit des cerebralen mikrozirkulationssystems. Naturwissenschaften, 1996, 83(7), 302-311.
160. Ohtsuki, S. New aspects of the blood-brain barrier transporters; its physiological roles in the central nervous system. Biol. Pharm. Bull., 2004, 27(10), 1489-1496.
161. Risau, W.; Engelhardt, B.; Wekerle, H. Immune function of the blood-brain barrier: incomplete presentation of protein (auto-)antigens by rat brain microvascular endothelium in vitro. J. Cell Biol., 1990, 110(5), 1757-1766.
162. el-Bacha, R.S.; Minn, A. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell. Mol. Biol., 1999, 45(1), 15-23.
163. Gilgun-Sherki, Y.; Melamed, E.; Offen, D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the
164. Pardridge, W. M. The blood-brain barrier and neurotherapeutics. Neurorx, 2005, 2(1), 1-2.
165. Bouchard, P.; Ghitescu, L. D.; Bendayan, M. Morpho-functional studies of the blood-brain barrier in streptozotocin-induced diabetic rats. Diabetologia, 2002, 45(7), 1017-1025.
166. Mooradian, A. D. Central nervous system complications of diabetes mellitus-a perspective from the blood-brain barrier. Brain Res. Rev., 1997, 23(3), 210-218.
167. Huber, J.D.; Egleton, R.D.; Davis, T.P. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci., 2001, 24(12), 719-725.
168. Butt, A.M.; Jones, H.C.; Abbott, N.J. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J. Physiol., 1990, 429, 47-62.
169. Cornford, E.M.; Hyman, S.; Cornford, M.E.; Landaw, E.M.; Delgado-Escueta, A.V. Interictal seizure resections show two configurations of endothelial Glut1 glucose transporter in the human blood-brain barrier. J. Cereb. Blood Flow Metab., 1998, 18(1), 26-42.
170. Oldendorf, W.H.; Cornford, M.E.; Brown, W.J. The large apparent work capability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann. Neurol., 1977, 1(5), 409-417.
171. Bell, R.D.; Zlokovic, B.V. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol., 2009, 118(1), 103-113.
172. Bendayan, R.; Lee, G.; Bendayan, M. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc. Res. Tech., 2002, 57(5), 365-380.
173. Dore-Duffy, P. Pericytes: pluripotent cells of the blood brain barrier. Curr. Pharm. Des., 2008, 14(16), 1581-1593.
174. Rucker, H.K.; Wynder, H.J.; Thomas, W.E. Cellular mechanisms of CNS pericytes. Brain Res. Bull., 2000, 51(5), 363-369.
175. Krause, D.; Kunz, J.; Dermietzel, R. Cerebral pericytes-a second line of defense in controlling blood-brain barrier peptide metabolism. Adv. Exp. Med. Biol., 1993, 331, 149-152.
176. Pardridge, W.M. Molecular biology of the blood-brain barrier. Mol. Biotechnol., 2005, 30(1), 57-70.
177. Abbott, N.J.; Ronnback, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci., 2006, 7(1), 41-53.
178. Tran, N.D.; Schreiber, S.S.; Fisher, M. Astrocyte regulation of endothelial tissue plasminogen activator in a blood-brain barrier model. J. Cereb. Blood Flow Metab., 1998, 18(12), 1316-1324.
179. Sauer, I. Apolipoprotein E Abgeleitete Peptide als Vektoren zur Überwindung der Blut-Hirn-Schranke. PhD Thesis. Freie Universität, Berlin, 2004.
180. Egleton, R.D.; Davis, T.P. Development of neuropeptide drugs that cross the blood-brain barrier. Neurorx, 2005, 2(1), 44-53.
181. Abbruscato, T.J.; Thomas, S.A.; Hruby, V.J.; Davis, T.P. Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine. J. Pharmacol. Exp. Ther., 1997, 280(1), 402-409.
182. Banks, W.A.; Schally, A.V.; Barrera, C.M.; Fasold, M.B.; Durham, D.A.; Csernus, V.J.; Groot, K.; Kastin, A.J. Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. Proc. Natl. Acad. Sci. U.S.A., 1990, 87(17), 6762-6766.
183. Cornford, E.M.; Hyman, S. Blood-brain barrier permeability to small and large molecules. Adv. Drug Deliv. Rev., 1999, 36(2-3), 145-163.
184. Bloch, O.; Manley, T.G. The role of aquaporin-4 in cerebral water transport and edema 1. Neurosurg. Focus, 2007, 22(5), E3.
185. Badaut, J.; Brunet, J.F.; Petit, J.M.; Guerin, C.F.; Magistretti, P.J.; Regli, L. Induction of brain aquaporin 9 (AQP9) in catecholaminergic neurons in diabetic rats. Brain Res., 2008, 1188, 17-24.
186. Badaut, J.; Brunet, J.F.; Regli, L. Aquaporins in the brain: from aqueduct to "multi-duct". Metab. Brain Dis., 2007, 22(3-4), 251-263.
187. Agus, D.B.; Gambhir, S.S.; Pardridge, W.M.; Spielholz, C.; Baselga, J.; Vera, J.C.; Golde, D.W. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J. Clin. Invest., 1997, 100(11), 2842-2848.
188. Dahlin, A.; Royall, J.; Hohmann, J. G.; Wang, J. Expression profiling of the solute carrier gene family in the mouse brain. J. Pharmacol. Exp. Ther., 2009, 329(2), 558-570.
189. Pardridge, W.M. Blood-brain barrier delivery. Drug Discov. Today, 2007, 12(1-2), 54-61.
190. Abbruscato, T.J.; Thomas, S.A.; Hruby, V.J.; Davis, T.P. Brain and spinal cord distribution of biphalin: correlation with opioid receptor density and mechanism of CNS entry. J. Neurochem., 1997, 69(3), 1236-1245.
191. Zlokovic, B.V.; Mackic, J.B.; Djuricic, B.; Davson, H. Kinetic analysis of leucine-enkephalin cellular uptake at the luminal side of the blood-brain barrier of an in situ perfused guinea-pig brain. J. Neurochem., 1989, 53(5), 1333-1340.
192. Zlokovic, B.V.; Hyman, S.; McComb, J.G.; Lipovac, M.N.; Tang, G.; Davson, H. Kinetics of arginine-vasopressin uptake at the blood-brain barrier. Biochim. Biophys. Acta, 1990, 1025(2), 191-198.
193. Thomas, S.A.; Abbruscato, T.J.; Hruby, V.J.; Davis, T.P. The entry of [D-penicillamine2, 5]enkephalin into the central nervous system: saturation kinetics and specificity. J. Pharmacol. Exp. Ther., 1997, 280(3), 1235-1240.
194. Begley, D.J. ABC transporters and the blood-brain barrier. Curr. Pharm. Des., 2004, 10(12), 1295-1312.
195. Scherrmann, J.M. Expression and function of multidrug resistance transporters at the blood brain barriers. Expert Opin. Drug Metab. Toxicol., 2005, 1(2), 233-246.
196. Löscher, W.; Potschka, H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. Neurorx, 2005, 2(1), 86-98.
197. Hosoya, K.; Sugawara, M.; Asaba, H.; Terasaki, T., Blood-brain barrier produces significant efflux of L-aspartic acid but not D-aspartic acid. J. Neurochem., 1999, 73(3), 1206-1211.
198. Pardridge, W.M. Transport of small molecules through the blood-brain barrier: biology and methodology. Adv. Drug Deliv. Rev., 1995, 15(1-3), 5-36.
199. Stahl, P.; Schwartz, A.L. Receptor-mediated endocytosis. J. Clin. Invest., 1986, 77(3), 657-662.
200. Roberts, R.L.; Fine, R.E.; Sandra, A. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J. Cell Sci., 1993, 104(Pt 2), 521-532.
201. Duffy, K.R.; Pardridge, W.M. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res., 1987, 420(1), 32-38.
202. Banks, W.A.; Kastin, A.J.; Huang, W.; Jaspan, J.B.; Maness, L.M. Leptin enters the brain by a saturable system independent of insulin. Peptides, 1996, 17(2), 305-311.
203. Duffy, K.R.; Pardridge, W.M.; Rosenfeld, R.G. Human blood-brain barrier insulin-like growth factor receptor. Metabolism., 1988, 37(2), 136-140.
204. Tamai, I.; Sai, Y.; Kobayashi, H.; Kamata, M.; Wakamiya, T.; Tsuji, A. Structure-internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier. J. Pharmacol. Exp. Ther., 1997, 280(1), 410-415.
205. Herve, F.; Ghinea, N.; Scherrmann, J.M. CNS delivery via adsorptive transcytosis. AAPS J., 2008, 10(3), 455-472.
206. Fischer, H.; Gottschlich, R.; Seelig, A. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J. Membr. Biol., 1998, 165(3), 201-211.
207. Pardridge, W.M. The blood-brain barrier: bottleneck in brain drug development. Neurorx, 2005, 2(1), 3-14.
208. Banks, W.A.; Freed, E.O.; Wolf, K.M.; Robinson, S.M.; Franko, M.; Kumar, V.B. Transport of human immunodeficiency virus type 1 pseudoviruses across the blood-brain barrier: role of envelope proteins and adsorptive endocytosis. J. Virol., 2001, 75(10), 4681-4691.
209. Weiss, N.; Miller, F.; Cazaubon, S.; Couraud, P.O. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim. Biophys. Acta, 2009, 1788(4), 842-857.
210. Pardridge, W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv., 2003, 3(2), 90-105, 51.
211. Newton, H.B. Advances in strategies to improve drug delivery to brain tumors. Expert Rev. Neurother., 2006, 6(10), 1495-1509.
212. Doolittle, N.D.; Peereboom, D.M.; Christoforidis, G.A.; Hall, W.A.; Palmieri, D.; Brock, P.R.; Campbell, K.C.; Dickey, D.T.; Muldoon, L.L.; O'Neill, B.P.; Peterson, D.R.; Pollock, B.; Soussain, C.; Smith, Q.; Tyson, R.M.; Neuwelt, E.A. Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting. J. Neurooncol., 2007, 81(1), 81-91.
213. Batrakova, E.V.; Miller, D.W.; Li, S.; Alakhov, V.Y.; Kabanov, A.V.; Elmquist, W.F. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J. Pharmacol. Exp. Ther., 2001, 296(2), 551-557.
214. Alakhov, V.; Klinski, E.; Li, S.; Pietrzynski, G.; Venne, A.; Batrakova, E.; Bronitch, T.; Kabanov, A. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf. B Biointerfaces, 1999, 16(1-4), 113-134.
215. Batrakova, E.V.; Li, S.; Vinogradov, S.V.; Alakhov, V.Y.; Miller, D.W.; Kabanov, A.V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther., 2001, 299(2), 483-493.
216. Fiorillo, A.; Maggi, G.; Greco, N.; Migliorati, R.; D'Amico, A.; De Caro, M.D.; Sabbatino, M.S.; Buffardi, F. Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors. J. Neurooncol., 2004, 66(1-2), 179-85.
217. Albrecht, K.W.; de Witt Hamer, P.C.; Leenstra, S.; Bakker, P.J.; Beijnen, J.H.; Troost, D.; Kaaijk, P.; Bosch, A.D. High concentration of daunorubicin and daunorubicinol in human malignant astrocytomas after systemic administration of liposomal daunorubicin. J. Neurooncol., 2001, 53(3), 267-271.
218. Fabel, K.; Dietrich, J.; Hau, P.; Wismeth, C.; Winner, B.; Przywara, S.; Steinbrecher, A.; Ullrich, W.; Bogdahn, U. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer, 2001, 92(7), 1936-1942.
219. Koukourakis, M.I.; Koukouraki, S.; Fezoulidis, I.; Kelekis, N.; Kyrias, G.; Archimandritis, S.; Karkavitsas, N. High intratumoral accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumors. Br. J. Cancer, 2000, 83(10), 1281-1286.
220. Zucchetti, M.; Boiardi, A.; Silvani, A.; Parisi, I.; Piccolrovazzi, S.; D'Incalci, M. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Cancer Chemother. Pharmacol., 1999, 44(2), 173-176.
221. DepoCyt(e)® (cytarabine liposome injection). Prescribing information. ScyPharma Inc. 2000.
222. Immordino, M.L.; Dosio, F.; Cattel, L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine, 2006, 1(3), 297-315.
223. Noble, C.O.; Krauze, M.T.; Drummond, D.C.; Yamashita, Y.; Saito, R.; Berger, M.S.; Kirpotin, D.B.; Bankiewicz, K.S.; Park, J.W. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res., 2006, 66(5), 2801-2806.
224. Arayne, M.S.; Sultana, N. Review: nanoparticles in drug delivery for the treatment of cancer. Pak J. Pharm. Sci., 2006, 19(3), 258-268.
225. Steiniger, S.C.; Kreuter, J.; Khalansky, A.S.; Skidan, I.N.; Bobruskin, A.I.; Smirnova, Z.S.; Severin, S.E.; Uhl, R.; Kock, M.; Geiger, K.D.; Gelperina, S.E. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer, 2004, 109(5), 759-767.
226. Olivier, J.C.; Fenart, L.; Chauvet, R.; Pariat, C.; Cecchelli, R.; Couet, W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res., 1999, 16(12), 1836-1842.
227. Gulyaev, A.E.; Gelperina, S.E.; Skidan, I.N.; Antropov, A.S.; Kivman, G.Y.; Kreuter, J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res., 1999, 16(10), 1564-1569.
228. Brigger, I.; Morizet, J.; Aubert, G.; Chacun, H.; Terrier-Lacombe, M.J.; Couvreur, P.; Vassal, G. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J. Pharmacol. Exp. Ther., 2002, 303(3), 928-936.
229. Calvo, P.; Gouritin, B.; Villarroya, H.; Eclancher, F.; Giannavola, C.; Klein, C.; Andreux, J.P.; Couvreur, P. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur. J. Neurosci., 2002, 15(8), 1317-1326.
230. Brigger, I.; Morizet, J.; Laudani, L.; Aubert, G.; Appel, M.; Velasco, V.; Terrier-Lacombe, M.J.; Desmaele, D.; d'Angelo, J.; Couvreur, P.; Vassal, G. Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J. Control. Release, 2004, 100(1), 29-40.
231. Garcia-Garcia, E.; Andrieux, K.; Gil, S.; Kim, H.R.; Le Doan, T.; Desmaele, D.; d'Angelo, J.; Taran, F.; Georgin, D.; Couvreur, P. A methodology to study intracellular distribution of nanoparticles in brain endothelial cells. Int. J. Pharm., 2005, 298(2), 310-314.
232. Costantino, L.; Gandolfi, F.; Tosi, G.; Rivasi, F.; Vandelli, M.A.; Forni, F. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Control. Release, 2005, 108(1), 84-96.
233. Tosi, G.; Costantino, L.; Rivasi, F.; Ruozi, B.; Leo, E.; Vergoni, A.V.; Tacchi, R.; Bertolini, A.; Vandelli, M.A.; Forni, F. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J. Control. Release, 2007, 122(1), 1-9.
234. Blasi, P.; Giovagnoli, S.; Schoubben, A.; Ricci, M.; Rossi, C. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev., 2007, 59(6), 454-477.
235. Yang, S.; Zhu, J.; Lu, Y.; Liang, B.; Yang, C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res., 1999, 16(5), 751-757.
236. Yang, S.C.; Lu, L.F.; Cai, Y.; Zhu, J.B.; Liang, B.W.; Yang, C.Z. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release, 1999, 59(3), 299-307.
237. Zara, G.P.; Cavalli, R.; Fundaro, A.; Bargoni, A.; Caputo, O.; Gasco, M.R. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol. Res., 1999, 40(3), 281-286.
238. Koziara, J.M.; Lockman, P.R.; Allen, D.D.; Mumper, R.J. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control. Release, 2004, 99(2), 259-269.
239. Vinogradov, S.V.; Batrakova, E.V.; Kabanov, A.V. Nanogels for oligonucleotide delivery to the brain. Bioconjug. Chem., 2004, 15(1), 50-60.
240. Kabanov, A.V.; Batrakova, E.V. New technologies for drug delivery across the blood brain barrier. Curr. Pharm. Des., 2004, 10(12), 1355-1363.
241. Dhanikula, R.S.; Hildgen, P. Influence of molecular architecture of polyether-co-polyester dendrimers on the encapsulation and release of methotrexate. Biomaterials, 2007, 28(20), 3140-3152.
242. Dhanikula, R.S.; Argaw, A.; Bouchard, J.F.; Hildgen, P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol. Pharm., 2008, 5(1), 105-116.
243. Dhanikula, R.S.; Hammady, T.; Hildgen, P. On the mechanism and dynamics of uptake and permeation of polyether-copolyester dendrimers across an in vitro blood-brain barrier model. J. Pharm. Sci., 2009, 98(10), 3748-3760.
244. Dhanikula, R.S.; Hildgen, P. Synthesis and evaluation of novel dendrimers with a hydrophilic interior as nanocarriers for drug delivery. Bioconjug. Chem., 2006, 17(1), 29-41.
245. de Boer, A.G.; Gaillard, P.J. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 323-355.
246. Lambkin, I.; Pinilla, C. Targeting approaches to oral drug delivery. Expert Opin. Biol. Ther., 2002, 2(1), 67-73.
247. Mudie, D.M.; Amidon, G.L.; Amidon, G.E. Physiological parameters for oral delivery and in vitro testing. Mol. Pharm., 2010, 7(5), 1388-1405.
248. O'Neill, M.J.; Bourre, L.; Melgar, S.; O'Driscoll, C.M. Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models. Drug Discov. Today, 2011, 16(5-6), 203-218.
249. Shakweh, M.; Ponchel, G.; Fattal, E. Particle uptake by Peyer̀s patches: a pathway for drug and vaccine delivery. Expert Opin. Drug Deliv., 2004, 1(1), 141-163.
250. Garinot, M.; Fievez, V.; Pourcelle, V.; Stoffelbach, F.; des Rieux, A.; Plapied, L.; Theate, I.; Freichels, H.; Jerome, C.; Marchand-Brynaert, J.; Schneider, Y.J.; Preat, V. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control. Release, 2007, 120(3), 195-204.
251. Laroui, H.; Wilson, D.S.; Dalmasso, G.; Salaita, K.; Murthy, N.; Sitaraman, S.V.; Merlin, D. Nanomedicine in GI. Am. J. Physiol. Gastrointest. Liver Physiol., 2011, 300(3), G371-G383.
252. Lai, S.K.; Wang, Y.Y.; Hanes, J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev., 2009, 61(2), 158-171.
253. Cone, R. A. Barrier properties of mucus. Adv. Drug Deliv. Rev., 2009, 61(2), 75-85.
254. Frey, A.; Giannasca, K.T.; Weltzin, R.; Giannasca, P.J.; Reggio, H.; Lencer, W.I.; Neutra, M.R. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J. Exp. Med., 1996, 184(3), 1045-1059
255. Gumbiner, B.M. Breaking through the tigh junction barrier. J. Cell Biol., 1993, 123(6), 1631-1633.
256. Kondoh, M.; Yagi, K. Progress in absorption enhancers based on tight junction. Expert Opin. Drug Deliv., 2007, 4(3), 275-286.
257. Matsuhisa, K.; Kondoh, M.; Takahashi, A.; Yagi, K. Tight junction modulator and drug delivery. Expert Opin. Drug Deliv., 2009, 6(5), 509-515.
258. Hugger, E.D.; Novak, B.L.; Burton, P.S.; Audus, K.L.; Borchardt, R.T. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J. Pharm. Sci., 2002, 91(9), 1991-2002.
259. McDevitt, C.A.; Callaghan, R. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol. Ther., 2007, 113(2), 429-441.
260. del Amo, E.M.; Heikkinen, A.T.; Monkkonen, J. In vitro-in vivo correlation in p-glycoprotein mediated transport in intestinal absorption. Eur. J. Pharm. Sci., 2009, 36(2-3), 200-211.
261. rd ed.; Churchill Livingstone Elsevier: Edinburgh; Toronto, 2007.
262. Devalapally, H.; Chakilam, A.; Amiji, M.M. Role of nanotechnology in pharmaceutical product development. J. Pharm. Sci., 2007, 96(10), 2547-2565.
263. Florence, A.T. The oral absorption of micro-and nanoparticulates: Neither exceptional nor unusual. Pharm. Res., 1997, 14(3), 259-266.
264. Plapied, L.; Duhem, N.; des Rieux, A.; Préat, V. Fate of polymeric nanocarriers for oral drug delivery. Curr. Opin. Colloid Interface Sci., 2011, 16(3), 228-237.
265. Florence, A.T.; Hillery, A.M.; Hussain, N.; Jani, P.U. Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J. Drug Target., 1995, 3(1), 65-70.
266. Kesisoglou, F.; Panmai, S.; Wu, Y.H. Nanosizing-Oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev., 2007, 59(7), 631-644.
267. Li, S.D.; Huang, L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm., 2008, 5(4), 496-504.
268. Mozafari, M.R.; Pardakhty, A.; Azarmi, S.; Jazayeri, J.A.; Nokhodchi, A.; Omri, A. Role of nanocarrier systems in cancer nanotherapy. J. Liposome Res., 2009, 19(4), 310-321.
269. Bravo-Osuna, I.; Vauthier, C.; Farabollini, A.; Palmieri, G. F.; Ponchel, G. Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials, 2007, 28(13), 2233-2243.
270. Bernkop-Schnürch, A.; Weithaler, A.; Albrecht, K.; Greimel, A. Thiomers: preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system. Int. J. Pharm., 2006, 317(1), 76-81.
271. Bromberg, L.; Temchenko, M.; Alakhov, V.; Hatton, T.A. Bioadhesive properties and rheology of polyether-modified poly(acrylic acid) hydrogels. Int. J. Pharm., 2004, 282(1-2), 45-60.
272. Lamprecht, A.; Schafer, U.; Lehr, C.M. Size-dependent bioadhesion of micro-and nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res., 2001, 18(6), 788-793.
273. Behrens, I.; Pena, A.I.V.; Alonso, M.J.; Kissel, T. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm. Res., 2002, 19(8), 1185-1193.
274. Sonaje, K.; Lin, K.J.; Wey, S.P.; Lin, C.K.; Yeh, T.H.; Nguyen, H.N.; Hsua, C.W.; Yen, T.C.; Juang, J.H.; Sung, H.W. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-Responsive nanoparticles vs. subcutaneous injection. Biomaterials, 2010, 31(26), 6849-6858.
275. Lai, S.K.; O'Hanlon, D.E.; Harrold, S.; Man, S.T.; Wang, Y.Y.; Cone, R.; Hanes, J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. U.S.A., 2007, 104(5), 1482-1487.
276. Jung, T.; Kamm, W.; Breitenbach, A.; Kaiserling, E.; Xiao, J.X.; Kissel, T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm., 2000, 50(1), 147-160.
277. des Rieux, A.; Fievez, V.; Garinot, M.; Schneider, Y.J.; Préat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release, 2006, 116(1), 1-27.
278. des Rieux, A.; Ragnarsson, E.G.; Gullberg, E.; Preat, V.; Schneider, Y.J.; Artursson, P. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur. J. Pharm. Sci., 2005, 25(4-5), 455-465.
279. Desai, M.P.; Labhasetwar, V.; Amidon, G.L.; Levy, R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res., 1996, 13(12), 1838-1845.
280. Vila, A.; Gill, H.; McCallion, O.; Alonso, M.J. Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J. Control. Release, 2004, 98(2), 231-244.
281. Otsuka, H.; Nagasaki, Y.; Kataoka, K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug Deliv. Rev., 2003, 55(3), 403-419.
282. Semete, B.; Booysen, L.; Lemmer, Y.; Kalombo, L.; Katata, L.; Verschoor, J.; Swai, H.S. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine, 2010, 6(5), 662-671.
283. Semete, B.; Booysen, L.I.; Kalombo, L.; Venter, J.D.; Katata, L.; Ramalapa, B.; Verschoor, J.A.; Swai, H. In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles. Toxicol. Appl. Pharmacol., 2010, 249(2), 158-165.
284. Peltier, S.; Oger, J.M.; Lagarce, F.; Couet, W.; Benoit, J.P., Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm. Res., 2006, 23(6), 1243-1250.
285. Roger, E.; Lagarce, F.; Garcion, E.; Benoit, J.P. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J. Control. Release, 2009, 140(2), 174-181.
286. Irache, J.M.; Durrer, C.; Duchêne, D.; Ponchel, G. Bioadhesion of lectin-latex conjugates to rat intestinal mucosa. Pharm. Res., 1996, 13(11), 1716-1719.
287. Yin, Y.; Chen, D.; Qiao, M.; Lu, Z.; Hu, H. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. J. Control. Release, 2006, 116(3), 337-345.
288. Umamaheshwari, R.B.; Ramteke, S.; Jain, N.K. Anti-Helicobacter pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gerbils model. AAPS PharmSciTech, 2004, 5(2) 60-68.
289. Clark, M.A.; Jepson, M.A.; Hirst, B.H. Exploiting M cells for drug and vaccine delivery. Adv. Drug Deliv. Rev., 2001, 50(1-2), 81-106.
290. Primard, C.; Rochereau, N.; Luciani, E.; Genin, C.; Delair, T.; Paul, S.; Verrier, B. Traffic of poly(lactic acid) nanoparticulate vaccine vehicle from intestinal mucus to sub-epithelial immune competent cells. Biomaterials, 2010, 31(23), 6060-6068.
291. Pan, Y.; Li, Y.J.; Zhao, H.Y.; Zheng, J.M.; Xu, H.; Wei, G.; Hao, J.S.; Cui, F.D. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int. J. Pharm., 2002, 249(1-2), 139-147.
292. Damge, C.; Michel, C.; Aprahamian, M.; Couvreur, P.; Devissaguet, J.P. Nanocapsules as carriers for oral peptide delivery. J. Control. Release, 1990, 13(2-3), 233-239.
293. Tobio, M.; Sanchez, A.; Vila, A.; Soriano, I.I.; Evora, C.; Vila-Jato, J.L.; Alonso, M.J. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf. B Biointerfaces, 2000, 18(3-4), 315-323.
294. Fricker, G.; Kromp, T.; Wendel, A.; Blume, A.; Zirkel, J.; Rebmann, H.; Setzer, C.; Quinkert, R.O.; Martin, F.; Muller-Goymann, C. Phospholipids and lipid-based formulations in oral drug delivery. Pharm. Res., 2010, 27(8), 1469-1486.
295. Jain, S.; Khomane, K.; Jain, A.K.; Dani, P. Nanocarriers for transmucosal vaccine delivery. Curr. Nanosci., 2011, 7(2), 160-177.
296. Zhang, N.; Ping, Q.; Huang, G.; Xu, W.; Cheng, Y.; Han, X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm., 2006, 327(1-2), 153-159.
297. Bromberg, L. Polymeric micelles in oral chemotherapy. J. Control. Release, 2008, 128(2), 99-112.
298. Gaucher, G.; Satturwar, P.; Jones, M.C.; Furtos, A.; Leroux, J.C. Polymeric micelles for oral drug delivery. Eur. J. Pharm. Biopharm., 2010, 76(2), 147-158.
299. Blanchette, J.; Kavimandan, N.; Peppas, N.A. Principles of transmucosal delivery of therapeutic agents. Biomed. Pharmacother., 2004, 58(3), 142-151.
300. Kim, S.; Shi, Y.; Kim, J.Y.; Park, K.; Cheng, J.X. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. Expert Opin. Drug Deliv., 2010, 7(1), 49-62.
301. Gaucher, G.; Marchessault, R.H.; Leroux, J.C. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J. Control. Release, 2010, 143(1), 2-12.
302. Mathot, F.; van Beijsterveldt, L.; Préat, V.; Brewster, M.; Ariën, A. Intestinal uptake and biodistribution of novel polymeric micelles after oral administration. J. Control. Release, 2006, 111(1-2), 47-55.
303. Blanchette, J.; Peppas, N.A. Cellular evaluation of oral chemotherapy carriers. J. Biomed. Mater. Res. Part A, 2005, 72(4), 381-388.
304. Sarmento, B.; Ribeiro, A.; Veiga, F.; Sampaio, P.; Neufeld, R.; Ferreira, D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm. Res., 2007, 24(12), 2198-2206.
305. Woitiski, C.B.; Neufeld, R.J.; Veiga, F.; Carvalho, R.A.; Figueiredo, I.V. Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. Eur. J. Pharm. Sci., 2010, 41(3-4), 556-563.
306. Yamamoto, A. Improvement of intestinal absorption of poorly absorbable drugs by polyamidoamine (PAMAM) dendrimers as novel absorption enhancers. Yakugaku Zasshi, 2010, 130(9), 1123-1127.
307. Jevprasesphant, R.; Penny, J.; Attwood, D.; McKeown, N.B.; D'Emanuele, A. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm. Res., 2003, 20(10), 1543-1550.
308. Gupta, U.; Agashe, H.B.; Jain, N.K. Polypropylene imine dendrimer mediated solubility enhancement: effect of pH and functional groups of hydrophobes. J. Pharm. Pharm. Sci., 2007, 10(3), 358-367.
309. Al-Jamal, K.T.; Ramaswamy, C.; Florence, A.T. Supramolecular structures from dendrons and dendrimers. Adv. Drug Deliv. Rev., 2005, 57(15), 2238-2270.
310. Todoroff, J.; Vanbever, R. Fate of nanomedicines in the lungs. Curr. Opin. Colloid Interface Sci., 2011, 16(3), 246-254.
311. Crapo, J.D.; Barry, B.E.; Gehr, P.; Bachofen, M.; Weibel, E.R. Cell number and cell characteristics of the normal human lung. Am. Rev. Respir. Dis., 1982, 125(6), 740-745.
312. Smola, M.; Vandamme, T.; Sokolowski, A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int. J. Nanomedicine, 2008, 3(1), 1-19.
313. Ware, L.B.; Matthay, M.A. The acute respiratory distress syndrome. N. Engl. J. Med., 2000, 342(18), 1334-1349.
314. Newman, S.P. Aerosol deposition considerations in inhalation therapy. Chest, 1985, 88(2), S152-S160.
315. Knowles, M.R.; Boucher, R.C. Mucus clearance as a primary innate defense mechanism for mammalian airways. J. Clin. Invest., 2002, 109(5), 571-577.
316. Sanders, N.; Rudolph, C.; Braeckmans, K.; De Smedt, S.C.; Demeester, J. Extracellular barriers in respiratory gene therapy. Adv. Drug Deliv. Rev., 2009, 61(2), 115-127.
317. Roy, I.; Vij, N. Nanodelivery in airway diseases: challenges and therapeutic applications. Nanomedicine, 2010, 6(2), 237-244.
318. Geiser, M.; Schurch, S.; Gehr, P. Influence of surface chemistry and topography of particles on their immersion into the lung's surface-lining layer. J. Appl. Physiol., 2003, 94(5), 1793-1801.
319. Wang, Y.Y.; Lai, S.K.; Suk, J.S.; Pace, A.; Cone, R.; Hanes, J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew. Chem. Int. Ed. Engl., 2008, 47(50), 9726-9729.
320. Patton, J. S. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev., 1996, 19(1), 3-36.
321. Oberdorster, G.; Sharp, Z.; Atudorei, V.; Elder, A.; Gelein, R.; Lunts, A.; Kreyling, W.; Cox, C. Extrapulmonary translocation of ultrafine carbon particles following whole-body inhalation exposure of rats. J. Toxicol. Environ. Health A, 2002, 65(20), 1531-1543.
322. Meiring, J.; Borm, P.; Bagate, K.; Semmler, M.; Seitz, J.; Takenaka, S.; Kreyling, W. The influence of hydrogen peroxide and histamine on lung permeability and translocation of iridium nanoparticles in the isolated perfused rat lung. Part. Fibre Toxicol., 2005, 2(1), 3.
323. Heckel, K.; Kiefmann, R.; Dorger, M.; Stoeckelhuber, M.; Goetz, A.E. Colloidal gold particles as a new in vivo marker of early acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol., 2004, 287(4), L867-L878.
324. Furuyama, A.; Kanno, S.; Kobayashi, T.; Hirano, S. Extrapulmonary translocation of intratracheally instilled fine and ultrafine particles via direct and alveolar macrophage-associated routes. Arch. Toxicol., 2009, 83(5), 429-437.
325. Takenaka, S.; Karg, E.; Kreyling, W.G.; Lentner, B.; Moeller, W.; Behnke-Semmler, M.; Jennen, L.; Walch, A.; Michalke, B.; Schramel, P.; Heyder, J.; Schulz, H. Distribution pattern of inhaled ultrafine gold particles in the rat lung. Inhal. Toxicol., 2006, 18(10), 733-740.
326. Chen, J.M.; Tan, M.G.; Nemmar, A.; Song, W.M.; Dong, M.; Zhang, G.L.; Li, Y. Quantification of extrapulmonary translocation of intratracheal-instilled particles in vivo in rats: Effect of lipopolysaccharide. Toxicology, 2006, 222(3), 195-201.
327. Yacobi, N.R.; Phuleria, H.C.; Dernaio, L.; Liang, C.H.; Peng, C.A.; Sioutas, C.; Borok, Z.; Kim, K.J.; Crandall, E.D. Nanoparticle effects on rat alveolar epithelial cell monolayer barrier properties. Toxicol. In Vitro, 2007, 21(8), 1373-1381.
328. Yacobi, N.; Fazllolahi, F.; Kim, Y.; Sipos, A.; Borok, Z.; Kim, K.J.; Crandall, E. Nanomaterial interactions with and trafficking across the lung alveolar epithelial barrier: implications for health effects of air-pollution particles. Air Quality, Atmosphere & Health, 2011, 4(1), 65-78.
329. Choi, H.S.; Ashitate, Y.; Lee, J.H.; Kim, S.H.; Matsui, A.; Insin, N.; Bawendi, M.G.; Semmler-Behnke, M.; Frangioni, J.V.; Tsuda, A. Rapid translocation of nanoparticles from the lung airspaces to the body. Nat. Biotechnol., 2010, 28(12), 1300-1003.
330. Kato, T.; Yashiro, T.; Murata, Y.; Herbert, D.; Oshikawa, K.; Bando, M.; Ohno, S.; Sugiyama, Y. Evidence that exogenous substances can be phagocytized by alveolar epithelial cells and transported into blood capillaries. Cell Tissue Res., 2003, 311(1), 47-51.
331. Edwards, D.A.; Ben-Jebria, A.; Langer, R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J. Appl. Physiol., 1998, 85(2), 379-385.
332. Oberdorster, G.; Oberdorster, E.; Oberdorster, J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect., 2005, 113(7), 823-839.
333. Moller, W.; Felten, K.; Sommerer, K.; Scheuch, G.; Meyer, G.; Meyer, P.; Haussinger, K.; Kreyling, W.G. Deposition, retention, and translocation of ultrafine particles from the central airways and lung periphery. Am. J. Respir. Crit. Care Med., 2008, 177(4), 426-432.
334. ElBaseir, M.M.; Phipps, M.A.; Kellaway, I.W. Preparation and subsequent degradation of poly(L-lactic acid) microspheres suitable for aerosolisation: a physico-chemical study. Int. J. Pharm., 1997, 151(2), 145-153.
335. Edwards, D.A.; Hanes, J.; Caponetti, G.; Hrkach, J.; Ben-Jebria, A.; Eskew, M.L.; Mintzes, J.; Deaver, D.; Lotan, N.; Langer, R. Large porous particles for pulmonary drug delivery. Science, 1997, 276(5320), 1868-1872.
336. French, D.L.; Edwards, D.A.; Niven, R.W. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J. Aerosol Sci., 1996, 27(5), 769-783.
337. Li, W.I.; Perzl, M.; Heyder, J.; Langer, R.; Brain, J.D.; Englemeier, K.H.; Niven, R.W.; Edwards, D.A. Aerodynamics and aerosol particle deaggregation
338. Brown, D.M.; Wilson, M.R.; MacNee, W.; Stone, V.; Donaldson, K. Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines. Toxicol. Appl. Pharmacol., 2001, 175(3), 191-199.
339. Schreier, H.; Gonzalezrothi, R.J.; Stecenko, A.A. Pulmonary delivery of liposomes. J. Control. Release, 1993, 24(1-3), 209-223.
340. Gilbert, B.E.; Six, H.R.; Wilson, S.Z.; Wyde, P.R.; Knight, V. Small particle aerosols of enviroxime-containing liposomes. Antiviral Res., 1988, 9(6), 355-365.
341. Thomas, D.A.; Myers, M.A.; Wichert, B.; Schreier, H.; Gonzalezrothi, R.J. Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers. Chest, 1991, 99(5), 1268-1270.
342. Myers, M.A.; Thomas, D.A.; Straub, L.; Soucy, D.W.; Niven, R.W.; Kaltenbach, M.; Hood, C.I.; Schreier, H.; Gonzalezrothi, R.J. Pulmonary effects of chronic exposure to liposome aerosols in mice. Exp. Lung Res., 1993, 19(1), 1-19.
343. Waldrep, J.C.; Arppe, J.; Jansa, K.A.; Knight, V. High dose cyclosporin A and budesonide-liposome aerosols. Int. J. Pharm., 1997, 152(1), 27-36.
344. Waldrep, J. C.; Gilbert, B. E.; Knight, C. M.; Black, M. B.; Scherer, P. W.; Knight, V.; Eschenbacher, W., Pulmonary delivery of beclomethasone liposome aerosol in volunteers-Tolerance and safety. Chest 1997, 111 (2), 316-323.
345. Niven, R.W.; Schreier, H. Nebulization of liposomes. I. effects of lipid composition. Pharm. Res., 1990, 7(11), 1127-1133.
346. Taylor, K.M.G.; Farr, S.J. Liposomes for drug delivery to the respiratory tract. Drug Dev. Ind. Pharm., 1993, 19(1-2), 123-142.
347. Leung, K.K.M.; Bridges, P.A.; Taylor, K.M.G. The stability of liposomes to ultrasonic nebulisation. Int. J. Pharm., 1996, 145(1-2), 95-102.
348. Torchilin, V. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res., 2007, 24(1), 1-16.
349. Knop, K.; Hoogenboom, R.; Fischer, D.; Schubert, U.S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl., 2010, 49(36), 6288-308.
350. Klein, J. Probing the interactions of proteins and nanoparticles. Proc. Natl. Acad. Sci. U.S.A., 2007, 104(7), 2029-2030.
351. Roach, P.; Farrar, D.; Perry, C.C. Surface tailoring for controlled protein adsorption: effect of topography at the nanometer scale and chemistry. J. Am. Chem. Soc., 2006, 128(12), 3939-3945.
352. Deng, Z.J.; Liang, M.; Monteiro, M.; Toth, I.; Minchin, R.F. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat Nanotechnol., 2011, 6(1), 39-44.
353. Paillard, A.; Passirani, C.; Saulnier, P.; Kroubi, M.; Garcion, E.; Benoit, J.P.; Betbeder, D. Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriers. Pharm. Res., 2010, 27(1), 126-133.
354. Merkel, T.J.; Jones, S.W.; Herlihy, K.P.; Kersey, F.R.; Shields, A.R.; Napier, M.; Luft, J.C.; Wu, H.L.; Zamboni, W.C.; Wang, A.Z.; Bear, J.E.; DeSimone, J.M. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc. Natl. Acad. Sci. U.S.A., 2011, 108(2), 586-591.
355. Kutscher, H.L.; Chao, P.; Deshmukh, M.; Sundara Rajan, S.; Singh, Y.; Hu, P.; Joseph, L.B.; Stein, S.; Laskin, D.L.; Sinko, P.J. Enhanced passive pulmonary targeting and retention of PEGylated rigid microparticles in rats. Int. J. Pharm., 2010, 402(1-2), 64-71.
356. Banquy, X.; Suarez, F.; Argaw, A.; Rabanel, J.M.; Grutter, P.; Bouchard, J.F.; Hildgen, P.; Giasson, S. Effect of mechanical properties of hydrogel nanoparticles on macrophage cell uptake. Soft Matter, 2009, 5(20), 3984-3991.